Key result
Prior ARNI linked to ~70% lower risk of initial eGFR dip upon SGLT2i initiation versus ARBs.
Why the study?
The impact of prior ARNI use on the initial eGFR dip following SGLT2 inhibitor initiation in patients with chronic kidney disease remains unclear.
Does prior ARNI use reduce the initial eGFR dip after SGLT2 inhibitor initiation in patients with chronic kidney disease compared to prior ARB use?
Cohort (n=157)
No
Does prior ARNI use reduce the initial eGFR dip after SGLT2 inhibitor initiation in patients with chronic kidney disease compared to prior ARB use?
Prior ARNI use may mitigate the initial eGFR dip following SGLT2 inhibitor initiation in patients with CKD, though it does not significantly alter the 1-year eGFR trajectory.
Answers are grounded in this paper and cite their sources.
Prior ARNI use may blunt SGLT2i eGFR dip in CKD; leaves open effects on long-term outcomes.
BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide cardiorenal protection; however, a transient decline in estimated glomerular filtration rate (eGFR), known as the ''initial dip'', is frequently observed after initiation. Although this phenomenon reflects changes in intraglomerular hemodynamics, excessive decline may be associated with worsening renal function. Angiotensin receptor-neprilysin inhibitors (ARNIs) have demonstrated renal protective effects in heart failure, but their impact on the initial dip after SGLT2 inhibitor initiation remains unclear. METHODS: We retrospectively evaluated the effect of prior ARNI use on the initial dip following SGLT2 inhibitor initiation in 157 patients with chronic kidney disease who newly started SGLT2 inhibitors between 2022 and 2025. Patients were classified into an ARNI group and an angiotensin receptor blocker (ARB) group. The primary outcome was the incidence of an initial dip, defined as a ≥ 5% decline in eGFR after SGLT2 inhibitor initiation. The secondary outcome was the change in eGFR and urine protein excretion at 1 year. RESULTS: The incidence of the initial dip did not significantly differ between the ARNI and ARB groups (30.0% vs. 46.5%, p = 0.10). However, multivariate logistic regression analysis showed that prior ARNI use was independently associated with a lower risk of initial dip (odds ratio 0.30, 95% CI 0.10-0.89, p = 0.02). Prior ARNI use was not significantly associated with longitudinal eGFR and urine protein changes at 1 year. CONCLUSIONS: Prior ARNI use was associated with a lower risk of the initial eGFR dip following SGLT2 inhibitor initiation, although prospective studies are needed to confirm these findings.
No takes yet. Share an insight, caveat, or question.
Ushio et al. (2026) conducted a cohort in Chronic kidney disease (n=157). Prior ARNI use vs. Prior ARB use was evaluated on Incidence of an initial dip, defined as a ≥ 5% decline in eGFR within 2 months after SGLT2 inhibitor initiation (OR 0.30, 95% CI 0.10-0.89, p=0.02). Prior ARNI use was independently associated with a lower risk of an initial eGFR dip following SGLT2 inhibitor initiation compared to prior ARB use.
Synapse has enriched 10 related papers. Consider them for comparative context: